Rhythm Biosciences logo

RHY - Rhythm Biosciences Share Price

A$0.895 0.0  2.9%

Last Trade - 14/05/21

Small Cap
Market Cap £99.2m
Enterprise Value £95.9m
Revenue £16.9k
Position in Universe 670th / 1911
Unlock RHY Revenue
Relative Strength (%)
1m -25.0%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -46.6%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.064 0.14 0.046
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 31 December 2020, RhythmBiosciences Ltd revenues decreased 60% to A$10K. Net lossincreased 5% to A$2M. Revenues reflect a decrease in demandfor the Company's products and services due to unfavorablemarket conditions. Higher net loss reflects Research anddevelopment costs increase of 61% to A$1.3M (expense),Office and compliance costs increase of 26% to A$360K(expense), Depreciation increase of 21% to A$61K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for RHY
Graphical History


RHY Revenue Unlock RHY Revenue

Net Income

RHY Net Income Unlock RHY Revenue

Normalised EPS

RHY Normalised EPS Unlock RHY Revenue

PE Ratio Range

RHY PE Ratio Range Unlock RHY Revenue

Dividend Yield Range

RHY Dividend Yield Range Unlock RHY Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
RHY EPS Forecasts Unlock RHY Revenue
Profile Summary

Rhythm Biosciences Limited is an Australia-based medical diagnostics technology company. The Company is engaged in developing and commercializing cancer diagnostics technology for sale to national and international markets. Its development stage product, ColoSTAT focuses to provide early detection test for colorectal cancer. ColoSTAT is a diagnostic test to augment screening programs. The Company's subsidiary, Vision Tech Bio Pty Ltd, owns the colorectal cancer diagnostic technology.

Last Annual June 30th, 2020
Last Interim December 31st, 2020
Incorporated June 1, 2017
Public Since December 7, 2017
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange Australian Stock Exchange - SEATS
Shares in Issue 201,495,811
Free Float (0.0%)
Eligible for
RHY Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for RHY
Upcoming Events for RHY
Frequently Asked Questions for Rhythm Biosciences
What is the Rhythm Biosciences share price?

As of 14/05/21, shares in Rhythm Biosciences are trading at A$0.895, giving the company a market capitalisation of £99.2m. This share price information is delayed by 15 minutes.

How has the Rhythm Biosciences share price performed this year?

Shares in Rhythm Biosciences are currently trading at A$0.895 and the price has moved by 0.954k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Rhythm Biosciences price has moved by 0.689k% over the past year.

What are the analyst and broker recommendations for Rhythm Biosciences?

There are no analysts currently covering Rhythm Biosciences.

When will Rhythm Biosciences next release its financial results?

Rhythm Biosciences is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Rhythm Biosciences dividend yield?

Rhythm Biosciences does not currently pay a dividend.

Does Rhythm Biosciences pay a dividend?

Rhythm Biosciences does not currently pay a dividend.

When does Rhythm Biosciences next pay dividends?

Rhythm Biosciences does not currently pay a dividend.

How do I buy Rhythm Biosciences shares?

To buy shares in Rhythm Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Rhythm Biosciences?

Shares in Rhythm Biosciences are currently trading at A$0.895, giving the company a market capitalisation of £99.2m.

Where are Rhythm Biosciences shares listed? Where are Rhythm Biosciences shares listed?

Here are the trading details for Rhythm Biosciences:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: RHY
What kind of share is Rhythm Biosciences?

Based on an overall assessment of its quality, value and momentum, Rhythm Biosciences is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Rhythm Biosciences share price forecast 2021?

We were not able to load any forecast data for Rhythm Biosciences.

How can I tell whether the Rhythm Biosciences share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Rhythm Biosciences. Over the past six months, the relative strength of its shares against the market has been 0.120k%. At the current price of A$0.895, shares in Rhythm Biosciences are trading at 18.66% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Rhythm Biosciences PE Ratio?

We were not able to find PE ratio data for Rhythm Biosciences.

Who are the key directors of Rhythm Biosciences?

Rhythm Biosciences's management team is headed by:

Trevor Lockett - DRC
Louis Panaccio - NED
David White - NED
Adrien Wing - SEC
Glenn Gilbert - CEO
Pauline Moffatt - SEC
Otto Buttula - CHM
Eduardo Vom - NED
Who are the major shareholders of Rhythm Biosciences?

Here are the top five shareholders of Rhythm Biosciences based on the size of their shareholding:

Buttula (Otto Leslie Steven) Individual Investor
Percentage owned: 13.55% (27.4m shares)
Wing (Adrien) Individual Investor
Percentage owned: 5.49% (11.1m shares)
Loumea Investments Pty. Ltd. Corporation
Percentage owned: 5.46% (11.0m shares)
Rojo Nero Capital Pty. Ltd. Corporation
Percentage owned: 2.06% (4.17m shares)
Cameron (Sarah) Individual Investor
Percentage owned: 1.49% (3.01m shares)
Similar to RHY
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.